Pros E - Search Results

1

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.

Alburquerque-Bejar JJ, Navajas-Chocarro P, Saigi M, Ferrero-Andres A, Morillas JM, Vilarrubi A, Gomez A, Mate JL, Munoz-Marmol AM, Romero OA, Blecua P, Davalos V, Esteller M, Pros E, Llabata P, Torres-Diz M, Esteve-Codina A, Sanchez-Cespedes M. Alburquerque-Bejar JJ, et al. Among authors: pros e. Cell Rep Med. 2023 Apr 18;4(4):101006. doi: 10.1016/j.xcrm.2023.101006. Epub 2023 Apr 11. Cell Rep Med. 2023. PMID: 37044092 Free PMC article.

2

Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients.

Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, Estivill X, Lázaro C. Ars E, et al. Among authors: pros e. J Med Genet. 2003 Jun;40(6):e82. doi: 10.1136/jmg.40.6.e82. J Med Genet. 2003. PMID: 12807981 Free PMC article. No abstract available.

3

Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH.

Garcia-Linares C, Fernández-Rodríguez J, Terribas E, Mercadé J, Pros E, Benito L, Benavente Y, Capellà G, Ravella A, Blanco I, Kehrer-Sawatzki H, Lázaro C, Serra E. Garcia-Linares C, et al. Among authors: pros e. Hum Mutat. 2011 Jan;32(1):78-90. doi: 10.1002/humu.21387. Hum Mutat. 2011. PMID: 21031597 Free PMC article.

4

Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations.

Pros E, Gómez C, Martín T, Fábregas P, Serra E, Lázaro C. Pros E, et al. Hum Mutat. 2008 Sep;29(9):E173-93. doi: 10.1002/humu.20826. Hum Mutat. 2008. PMID: 18546366

5

Tumor LOH analysis provides reliable linkage information for prenatal genetic testing of sporadic NF1 patients.

Serra E, Pros E, García C, López E, Gili ML, Gómez C, Ravella A, Capellá G, Blanco I, Lázaro C. Serra E, et al. Among authors: pros e. Genes Chromosomes Cancer. 2007 Sep;46(9):820-7. doi: 10.1002/gcc.20468. Genes Chromosomes Cancer. 2007. PMID: 17563086

6

Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors.

Rodriguez-Nieto S, Cañada A, Pros E, Pinto AI, Torres-Lanzas J, Lopez-Rios F, Sanchez-Verde L, Pisano DG, Sanchez-Cespedes M. Rodriguez-Nieto S, et al. Among authors: pros e. Hum Mutat. 2011 Feb;32(2):E1999-2017. doi: 10.1002/humu.21415. Epub 2010 Dec 7. Hum Mutat. 2011. PMID: 21280140

7

MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.

Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M. Romero OA, et al. Among authors: pros e. Cancer Discov. 2014 Mar;4(3):292-303. doi: 10.1158/2159-8290.CD-13-0799. Epub 2013 Dec 20. Cancer Discov. 2014. PMID: 24362264

8

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M. Pereira C, et al. Among authors: pros e. Clin Cancer Res. 2017 Jun 15;23(12):3203-3213. doi: 10.1158/1078-0432.CCR-16-1946. Epub 2017 Mar 16. Clin Cancer Res. 2017. PMID: 28302866

9

Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.

Gimenez-Xavier P, Pros E, Bonastre E, Moran S, Aza A, Graña O, Gomez-Lopez G, Derdak S, Dabad M, Esteve-Codina A, Hernandez Mora JR, Salinas-Chaparro D, Esteller M, Pisano D, Sanchez-Cespedes M. Gimenez-Xavier P, et al. Among authors: pros e. Mol Cancer Ther. 2017 Jul;16(7):1366-1376. doi: 10.1158/1535-7163.MCT-17-0104. Epub 2017 Apr 10. Mol Cancer Ther. 2017. PMID: 28396363

10

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.

Saigi M, McLeer-Florin A, Pros E, Nadal E, Brambilla E, Sanchez-Cespedes M. Saigi M, et al. Among authors: pros e. Clin Transl Oncol. 2018 Jul;20(7):881-888. doi: 10.1007/s12094-017-1799-7. Epub 2017 Nov 14. Clin Transl Oncol. 2018. PMID: 29139039

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page